Potential for Collaboration
Epidemiologists and Clinicians, Biochemists and Chemists
It is often difficult to prove whether or not a particular environmental factor, such as a pollutant, causes or exacerbates a specific disease. One reason for this difficulty is that rarely is information gathered to determine how much of a particular chemical an individual or group of people has been exposed to. Few studies are designed to assess a particular health outcome from a specific exposure in large groups of people over long periods of time. Furthermore, when we study people, we often only have access to their medical records and maybe blood samples. However, when our body fights an infection or someone has a disease caused by deregulation of their immune system, the relevant place to look at what is going on is frequently not the blood, but an organ within the body. These complications make it difficult to measure changes to immune function in people, and lead to gaps in our understanding of the effects of these toxins. Partnership between epidemiologists, clinicians, biochemists and immunologists will help us better resolve these unknowns, and make advancements toward better understanding the contribution of environmental exposures to human health and disease.
Pharmacologists and Clinicians
It was recently discovered that some naturally derived products, such as compounds in foods we eat, as well as possible new drugs work through the AhR to modify immune responses. This discovery means that it may be possible to develop more effective and less toxic immunotherapies to help the body fight off infections, or to treat allergic and autoimmune diseases. But, in order to use AhR as an effective target for immunotherapy, there needs to be a better understanding of how the many chemicals that bind to it alter the function of the immune system. There also needs to be a means of testing possible disease treatments in relevant model systems. Partnership with pharmacologists and clinicians would be advantageous to the development and testing of potential immune treatments that work through the AhR.
- Effects of Developmental Activation of the AhR on CD4(+) T-Cell Responses to Influenza Virus Infection in Adult Mice. Environ Health Perspect. In press. (2014 Jul 22).
- Negative effects of low dose atrazine exposure on the development of effective immunity to FV3 in Xenopus laevis. Dev Comp Immunol. 47, 52-58. (2014 Jun 28).
- New insights into the role of the aryl hydrocarbon receptor in the function of CD11c⁺ cells during respiratory viral infection. Eur J Immunol. 44, 1685-98. (2014 Jun 01).